MEI Pharma To Present At Needham Healthcare Conference

            MEI Pharma To Present At Needham Healthcare Conference

Live Webcast from New York on Tuesday, April 8th

PR Newswire

SAN DIEGO, April 1, 2014

SAN DIEGO, April 1, 2014 /PRNewswire/ --MEI Pharma, Inc. (Nasdaq: MEIP), an
oncology company focused on the clinical development of novel therapies for
cancer, announced today that Daniel P. Gold, Ph.D., President and Chief
Executive Officer, will present at the Needham Healthcare Conference on
Tuesday, April 8, 2014 at 3:00 p.m. Eastern time from the Westin Grand Central
Hotel in New York City. A live webcast of the presentation can be accessed at A replay will be available approximately one hour after the

MEI Pharma Logo.

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused
on the clinical development of novel therapies for cancer. The Company's lead
drug candidate is Pracinostat, a potential best-in-class, oral histone
deacetylase (HDAC) inhibitor currently being developed for myelodysplastic
syndrome (MDS) and acute myeloid leukemia (AML). Results from a pilot Phase II
clinical trial of Pracinostat in combination with Vidaza^® (azacitidine) in
patients with advanced MDS showed an overall response rate of 90% (nine of
10). MEI Pharma is also developing ME-344, a mitochondrial inhibitor that has
shown preliminary evidence of single-agent activity in a first-in-human
clinical study in patients with refractory solid tumors, including eight of 21
evaluable patients (38%) who achieved stable disease or better. In September
2013, the Company further expanded its pipeline of drug candidates with the
acquisition of PWT143, a highly selective PI3-kinase delta inhibitor. For more
information, go to

Under U.S. law, a new drug cannot be marketed until it has been investigated
in clinical trials and approved by the FDA as being safe and effective for the
intended use. Statements included in this press release that are not
historical in nature are "forward-looking statements" within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ materially
from those contained in the forward-looking statements, which are based on
management's current expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to successfully
commercialize our product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such approval, of our product
candidates; uncertainties or differences in interpretation in clinical trial
results; our inability to maintain or enter into, and the risks resulting from
our dependence upon, collaboration or contractual arrangements necessary for
the development, manufacture, commercialization, marketing, sales and
distribution of any products; competitive factors; our inability to protect
our patents or proprietary rights and obtain necessary rights to third party
patents and intellectual property to operate our business; our inability to
operate our business without infringing the patents and proprietary rights of
others; general economic conditions; the failure of any products to gain
market acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry practice;
and one-time events. We do not intend to update any of these factors or to
publicly announce the results of any revisions to these forward-looking


SOURCE MEI Pharma, Inc.

Contact: Pete De Spain, Vice President, Investor Relations & Corporate
Communications, (858) 792-3729,
Press spacebar to pause and continue. Press esc to stop.